Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PMA's NEW SENIOR VP FOR POLICY & ADMINISTRATION IS ROBERT ALLNUTT

Executive Summary

PMA's NEW SENIOR VP FOR POLICY & ADMINISTRATION IS ROBERT ALLNUTT, the assn. announced in an April 9 press release. Allnutt will be responsible for administrative matters for the assn., including relations with member companies and with PMA's Policy Analysis Office, the release states. Currently a vice president of Communications Satellite Corp. (ComSat), he will assume the newly created post at PMA May 6. The assn. also announced that VP-General Counsel Bruce Brennan and VP-Inter-natl. Jay Kingham have been promoted to the senior VP level. "My goal is to have PMA recognized as the most efficient industry assn. in Washington," assn. President Mossinghoff said in the release. "The organizational and staffing steps we are now taking are aimed in that direction." Brennan's and Kingham's promotions became effective April 8. The new appointments are the first significant staff changes Mossinghoff has made since joining the assn. in February. The new senior VP will move into policy positions which have been vacant since several top MPA staffers left following the resignation of former President Lewis Engman. The assn.'s future policy direction is also reflected in the new staff changes. For example, international issues -- including foreign patents and the initiative before the World Health Organization to adopt a world pharmaceutical marketing code -- are among the assn.'s top priorities. Kingham's experience is a key factor in PMA's efforts in those areas. Allnutt and Mossinghoff have been friends since they were law students at George Washington University in Washington, D.C. Their careers again overlapped at the Natl. Aeronautics & Space Administration, where Allnutt held a series of senior positions from 1978-1983 and Mossinghoff served as general counsel and legislative liaison. While at NASA, Allnutt earned the agency's Exceptional Service Medal and Distinguished Service Mdeal, and in 1981 he received the Presidential Rank of Meritorious Executive. Between his tenures at NASA and ComSat, he was VP and legal counsel for the U.S. Cmte. for Energy Awareness, a trade assn. representing the electric power industry. Prior to his experience at NASA, Allnutt, 49, was asst. general counsel for legislation at the Energy Dept. from 1977-1978; deputy asst. and asst. administrator of the Energy Research & Development Administration from 1975-1977; and staff director and counsel of the U.S. Senate Aeronautical & Space Sciences Cmte. Allnutt earned a B.S. in Industrial Engineering at Virginia Polytechnic Institute in 1957 and two law degrees -- J.D. and Master of Laws -- from George Washington University. Allnutt will be responsible for PMA's administrative and budgeting staff and its policy analysis staff, he told "The Pink Sheet." He added that his legal training and experience in external relations, lobbying, public affairs, and administration in other fields will be helpful in his new position. One element common to his previous areas of endeavor and the pharmaceutical industry is research and development, he said.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS008176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel